TY - JOUR
T1 - 3,3',4,4'-Tetrachloroazobenzene absorption, disposition, and metabolism in male Fischer 344 rats
AU - Pillai, U. A.
AU - Ziegler, T. L.
AU - Wang, D. X.
AU - Kattnig, M. J.
AU - McClure, T.
AU - Liebler, D. C.
AU - Mayersohn, M.
AU - Sipes, I. G.
PY - 1996
Y1 - 1996
N2 - 3,3',4,4'-Tetrachloroazobenzene (TCAB) is a contaminant generated during the synthesis of 3,4-dichloroaniline and 3,4-dichloroaniline-derived pesticides. TCAB is isosteric to 2,3,7,8-tetrachlorodibenzo-p-dioxin and has been shown to bind to the Ah receptor. Following oral administration of [14C]TCAB (3.2 and 32 mg/kg), 39-45% of the dosed radioactivity was excreted into the urine and 53-56% was recovered in the faces within 48 hr. Less than 6% of the dosed radioactivity remained in the tissues examined at 96 hr. After intravenous administration (3.2 mg/kg), 33% of the dose was excreted in the bile during 6 hr. TCAB metabolites in urine were identified using LC/MS. The major metabolites were sulfate ester conjugates of hydroxylated mono- or dichloroaniline derivatives. Some of these metabolites were also acetylated. After intravenous administration, the disappearance of [14C]TCAB from blood was monitored, and the pharmacokinetic profile was consistent with a two-compartment model. Pharmacokinetic parameters reveal that the compound is readily cleared from the blood with a t( 1/2 ) of 4.0 hr, clearance of 12.3 ml/min · kg, and an apparent volume of distribution of 4.3 liters/kg. The absolute oral bioavailability was determined to be 30%. The extensive azo reduction of TCAB decreases its systemic absorption after oral administration and thereby limits the amount of parent compound available to interact with the Ah receptor and decreases the Ah receptor-mediated toxicity.
AB - 3,3',4,4'-Tetrachloroazobenzene (TCAB) is a contaminant generated during the synthesis of 3,4-dichloroaniline and 3,4-dichloroaniline-derived pesticides. TCAB is isosteric to 2,3,7,8-tetrachlorodibenzo-p-dioxin and has been shown to bind to the Ah receptor. Following oral administration of [14C]TCAB (3.2 and 32 mg/kg), 39-45% of the dosed radioactivity was excreted into the urine and 53-56% was recovered in the faces within 48 hr. Less than 6% of the dosed radioactivity remained in the tissues examined at 96 hr. After intravenous administration (3.2 mg/kg), 33% of the dose was excreted in the bile during 6 hr. TCAB metabolites in urine were identified using LC/MS. The major metabolites were sulfate ester conjugates of hydroxylated mono- or dichloroaniline derivatives. Some of these metabolites were also acetylated. After intravenous administration, the disappearance of [14C]TCAB from blood was monitored, and the pharmacokinetic profile was consistent with a two-compartment model. Pharmacokinetic parameters reveal that the compound is readily cleared from the blood with a t( 1/2 ) of 4.0 hr, clearance of 12.3 ml/min · kg, and an apparent volume of distribution of 4.3 liters/kg. The absolute oral bioavailability was determined to be 30%. The extensive azo reduction of TCAB decreases its systemic absorption after oral administration and thereby limits the amount of parent compound available to interact with the Ah receptor and decreases the Ah receptor-mediated toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0030066099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030066099&partnerID=8YFLogxK
M3 - Article
C2 - 8742237
AN - SCOPUS:0030066099
SN - 0090-9556
VL - 24
SP - 238
EP - 244
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 2
ER -